Patents by Inventor Yu-Waye Chu

Yu-Waye Chu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
    Publication number: 20250073212
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: May 10, 2024
    Publication date: March 6, 2025
    Applicant: Genentech, Inc.
    Inventors: Andrew POLSON, Shang-Fan YU, Yu-Waye CHU, Michael WENGER, Jamie Harue HIRATA, Dan LU
  • OFF-THE-SHELF IPSC-DERIVED CAR-NK CELL AS MONOTHERAPY AND IN COMBINATION WITH ANTIBODY
    Publication number: 20240382523
    Abstract: Provided are methods and compositions for use in cancer immunotherapies. Exemplary compositions include functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In some embodiments, derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: August 18, 2022
    Publication date: November 21, 2024
    Inventors: Bahram VALAMEHR, Yu-Waye CHU
  • DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
    Publication number: 20240376223
    Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
    Type: Application
    Filed: July 26, 2024
    Publication date: November 14, 2024
    Inventors: Yu-Waye Chu, Iraj Hosseini, Saroja Ramanujan, Kapil Gadkar, Chi-Chung Li
  • Methods of using anti-CD79b immunoconjugates
    Patent number: 12016842
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: June 25, 2024
    Assignee: Genentech, Inc.
    Inventors: Andrew Polson, Shang-Fan Yu, Yu-Waye Chu, Michael Wenger, Jamie Harue Hirata, Dan Lu
  • DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
    Publication number: 20240132613
    Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
    Type: Application
    Filed: December 6, 2023
    Publication date: April 25, 2024
    Inventors: Yu-Waye CHU, Iraj HOSSEINI, Saroja RAMANUJAN, Kapil GADKAR, Chi-Chung LI
  • OFF-THE-SHELF iPSC-DERIVED NK CELL THERAPY FOR HEMATOLOGICAL CANCER TREATMENT
    Publication number: 20240100092
    Abstract: Provided are methods and compositions for use in cancer immunotherapies. In various embodiments, the compositions include functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In various embodiments, the derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: December 3, 2021
    Publication date: March 28, 2024
    Inventors: Bahram VALAMEHR, Yu-Waye CHU
  • DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
    Publication number: 20230242659
    Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
    Type: Application
    Filed: February 23, 2023
    Publication date: August 3, 2023
    Inventors: Yu-Waye Chu, Iraj Hosseini, Saroja Ramanujan, Kapil Gadkar, Chi-Chung Li
  • Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
    Patent number: 11466094
    Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: October 11, 2022
    Assignee: Genentech, Inc.
    Inventors: Yu-Waye Chu, Iraj Hosseini, Saroja Ramanujan, Kapil Gadkar, Chi-Chung Li
  • DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND ANTI-CD79B ANTIBODY DRUG CONJUGATES
    Publication number: 20220153842
    Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.
    Type: Application
    Filed: November 2, 2021
    Publication date: May 19, 2022
    Inventors: Chi-Chung LI, Carol Elaine O'HEAR, Stephen James SIMKO, III, Iris Tranthuyngan TO, Klara TOTPAL, Hong WANG, Michael C. WEI, Shen YIN, Brendan Christian BENDER, Xi CHEN, Yu-Waye CHU, Maria HRISTOPOULOS
  • METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
    Publication number: 20220040153
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: April 14, 2021
    Publication date: February 10, 2022
    Applicant: Genentech, Inc.
    Inventors: Andrew POLSON, Shang-Fan YU, Yu-Waye CHU, Michael WENGER, Jamie Harue HIRATA, Dan LU
  • METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
    Publication number: 20210346352
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: May 10, 2021
    Publication date: November 11, 2021
    Applicant: Genentech, Inc.
    Inventors: Andrew POLSON, Shang-Fan YU, Yu-Waye CHU, Michael WENGER, Jamie Harue HIRATA, Dan LU
  • Methods of using anti-CD79b immunoconjugates
    Patent number: 11000510
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: May 11, 2021
    Assignee: Genentech, Inc.
    Inventors: Andrew Polson, Shang-Fan Yu, Yu-Waye Chu, Michael Wenger, Jamie Harue Hirata, Dan Lu
  • METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
    Publication number: 20190201382
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: March 19, 2019
    Publication date: July 4, 2019
    Applicant: Genentech, Inc.
    Inventors: Andrew POLSON, Shang-Fan YU, Yu-Waye CHU, Michael WENGER
  • DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
    Publication number: 20180134798
    Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
    Type: Application
    Filed: November 15, 2017
    Publication date: May 17, 2018
    Inventors: Yu-Waye CHU, Iraj HOSSEINI, Saroja RAMANUJAN, Kapil GADKAR, Chi-Chung LI
  • METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
    Publication number: 20170304438
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: February 23, 2017
    Publication date: October 26, 2017
    Applicant: Genentech, Inc.
    Inventors: Andrew Polson, Shang-Fan Yu, Yu-Waye Chu, Michael Wenger
  • METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
    Publication number: 20160082120
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: September 23, 2015
    Publication date: March 24, 2016
    Applicant: GENENTECH, INC.
    Inventors: Andrew Polson, Shang-Fan Yu, Yu-Waye Chu, Michael Wenger